
PHOENIX—Mayo Clinic's campus in Phoenix, Arizona, has been identified as having the highest one-year patient survival rate in the U.S. for adult liver transplantation. The statistics include both deceased and living-donor liver transplants. These statistics indicate that 98.52 percent of all patients are living one year following their liver transplant – best in the nation. This compares with the national average of 90.83 percent. Mayo also leads the nation in three-year living donor liver transplant patient and graft (the organ) survival. The one-year patient survival rate for living donor liver transplant is 100 percent, and the three-year patient survival is highest in the nation at 96.3 percent.
PHOENIX — In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic. Their findings will be reported online Dec. 6 in the New England Journal of Medicine, and presented on Dec. 7 at the annual meeting of the American Society of Hematology (ASH), held in San Francisco. http://youtu.be/F-dSkfoi3gg Interim analysis of the ASPIRE clinical trial, which enrolled 792 patients with relapsed multiple myeloma from 20 countries, found an “unprecedented” prolongation of the time patients were free of disease progression, says the study’s lead investigator, Keith Stewart, M.B., Ch.B, a Mayo Clinic oncologist in Arizona. “Patients taking three drugs — carfilzomib, lenalidomide and dexamethasone — stayed free of disease progression for 26 months on average,” he says. “No one has reported anything like this before for relapsed multiple myeloma.”
An online patient support community